Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1383
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded112    
    Comments [Add]    

Recommend this journal


Year : 2017  |  Volume : 54  |  Issue : 1  |  Page : 223-227

The efficacy and safety of preoperative chemotherapy for patients with nonsmall cell lung cancer: A meta-analysis

Department of Thoracic Surgery, Peking University Third Hospital, Beijing 100191, China

Correspondence Address:
Dr. T Yan
Department of Thoracic Surgery, Peking University Third Hospital, Beijing 100191
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijc.IJC_60_17

Rights and Permissions

BACKGROUND: The efficacy of surgery alone for patients with nonsmall cell lung cancer (NSCLC) is still unsatisfactory. Preoperative chemotherapy (PCT) is proven effective induction therapies followed by surgery; however, few their superiority remains uncertain. We performed a systemic review and meta-analysis to evaluate the safety and efficacy of the PCT for NSCLC patients. MATERIALS AND METHODS: A literature search was performed in the PubMed, China National Knowledge Infrastructure and Cochrane databases. NSCLC patients treated with PCT plus surgery (PCT-S) or surgery (S) alone between 2006 and 2016 were analyzed. RESULTS: A total of eleven studies, involving a total of 2999 patients, were finally enrolled in this meta-analysis. Meta-analysis shows that PCT-S might have lower recurrence rate than S (odds ratio [OR] = 0.75, 95% confidence interval [CI] [0.60, 0.94], P = 0.01). However, no differences were found between two groups in overall survival rate (OR = 1.26, 95% CI [0.92, 1.72], P = 0.15) and (OR = 1.12, 95% CI [0.93, 1.33], P = 0.23), 3-year disease-free survival rate (OR = 1.22, 95% CI [0.73, 2.04], P = 0.44) and intraoperative and postoperative complication rates (OR = 1.24, 95% CI [0.89,1.74], P = 0.20). CONCLUSIONS: Two treatments have similar safety and efficacy. However, PCT can reduce the rate of local and distant recurrence, which is an independent risk factor for NSCLC prognosis and may improve the prognosis of NSCLC.


Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow